



# Boletín Médico del Hospital Infantil de México

www.elsevier.es



## RESEARCH ARTICLE

# Inflammatory cytokines adiponectin, resistin, IL-6 and IFN- $\gamma$ are associated with insulin resistance in eutrophic and obese children

Miguel Klünder-Klünder,<sup>a</sup> Miguel Cruz,<sup>b</sup> Rebeca García-Macedo,<sup>b</sup> Samuel Flores-Huerta<sup>a,\*</sup>

<sup>a</sup>Community Health Research Department, Hospital Infantil de México Federico Gómez, Ministry of Health (SSA), Mexico City, Mexico

<sup>b</sup>Medical Research Unit in Biochemistry, Unidad Médica de Alta Especialidad Bernardo Sepúlveda, Centro Médico Nacional Siglo XXI, IMSS, Mexico City, Mexico

Received 2 September 2013; accepted 2 October 2013

## KEYWORDS

Obesity;  
Cytokine;  
Child;  
Insulin resistance

## Abstract

**Background:** Obesity, a worldwide health problem, is associated with the increase of noncommunicable diseases. Excess adipose tissue above what is expected produces a cytokine imbalance decreasing adiponectin—an anti-inflammatory cytokine—and increasing those proinflammatory cytokines such as resistin, IL-6 and IFN- $\gamma$ . This imbalance elicits a low-degree systemic inflammation associated with insulin resistance (IR). Therefore, the aim of this study was to determine the relationship between pro- and anti-inflammatory cytokines levels with IR in eutrophic and obese Mexican children.

**Methods:** A cross-sectional study was conducted in 183 school-age children classified as obese and 186 children classified as eutrophic. Adiponectin, resistin, IL-6 and IFN- $\gamma$ , glucose, insulin, high-density lipoprotein cholesterol and triglycerides were determined from a fasting blood sample. Height, weight, waist circumference, and systolic and diastolic blood pressures were measured. Spearman correlation and linear regression analysis were used to assess the association between cytokines and IR.

**Results:** Anthropometric and metabolic measurements as well as adiponectin concentrations were statistically different between eutrophic and obese children ( $p < 0.001$ ). Adiponectin concentrations were  $12.5 \pm 5.0$  and  $10.8 \pm 4.2 \mu\text{g/mL}$  ( $p < 0.018$ ) for obese subjects without IR and obese subjects with IR. Resistin concentrations were  $11.7 \pm 7.5$  and  $14.2 \pm 7.8 \text{ ng/mL}$  ( $p = 0.026$ ), respectively. Linear regression showed that the HOMA-IR decreased  $-0.04$  units ( $p = 0.003$ ) by unit of change of adiponectin. Whereas the association with resistin was opposite, the HOMA-IR units increased  $0.02$  by unit of change in resistin ( $p = 0.018$ ).

**Conclusions:** In this sample of eutrophic and obese Mexican children, adiponectin concentrations were inversely related with IR contrary to resistin, whose levels were directly related.

© 2013 Boletín Médico del Hospital Infantil de México. Published by Masson Doyma México S.A. All rights reserved.

\*Corresponding author.

E-mail address: floreshuertamd@gmail.com (S. Flores-Huerta).

## Introduction

Obesity in children is a worldwide health problem.<sup>1</sup> In México, the prevalence of obesity has increased in the last 20 years.<sup>2</sup> The National Health Survey and Nutrition (ENSANUT, 2006) reported, between 1999 and 2006, a dramatic increase of obesity in school-age children (77% in boys and 47% in girls).<sup>3</sup> These figures remain almost the same in the Mexican ENSANUT, 2012.<sup>4</sup> It is well known that obesogenic environments and shifts in lifestyle where energy ingested is greater than energy expended are at the core of this problem.<sup>5</sup> Obesity is the most common cause of insulin resistance (IR) which, in turn, represents the common pathophysiological mechanism for metabolic alterations that are associated with the subsequent chronic illnesses such as hypertension and type 2 diabetes (T2D).<sup>6,7</sup> In the recent past, these were typically adult diseases, but nowadays are appearing during childhood.

When adipose tissue increases more than expected, a cytokine imbalance appears, increasing the release of pro-inflammatory cytokines such as TNF- $\alpha$ , IL-6, IL-1 $\beta$ , resistin, and leptin, whereas adiponectin—an anti-inflammatory cytokine—decreases.<sup>8,9</sup> This imbalance produces a chronic low-grade inflammation.<sup>10,11</sup>

It is currently accepted that alterations such as IR, endothelial dysfunction, atherosclerosis<sup>12-14</sup> and subsequent cardiovascular events are consequences of this low-grade state of inflammation.<sup>15</sup> Adiponectin protein is exclusively produced by adipocytes and plays a role in energy homeostasis and fatty acid oxidation as well as in reducing plasma triglycerides.<sup>16</sup> Although it negatively correlates with body fat,<sup>17,18</sup> the relationship with metabolic impairments in obese children remains controversial.<sup>19,20</sup>

On the other hand, resistin, whose levels augment in diet-induced obesity as well as in genetic models of obesity and insulin resistance, has proposed to link obesity with diabetes due to its insulin antagonism. However, these results are inconsistent in humans. Some studies did not find differences in the concentration of resistin between lean and obese children or an effect on insulin resistance.<sup>21,22</sup> Other groups did not find consistent associations,<sup>23</sup> whereas others reported that adults with high resistin levels have a higher risk for heart failure.<sup>24</sup>

Likewise, human adipose tissue is the main site of IL-6 production, although it is also released by cells such as T lymphocytes, macrophages, and muscle cells. IL-6 is the major determinant of the hepatic production of C-reactive protein, a mechanism that can explain the link between low-grade inflammation during obesity and IR. Similarly, IL-6 secretion is induced during exercise. In this case, IL-6 acts as a myokine, functioning as an energy sensor by activating AMP-activated protein kinase and enhancing glucose disposal and, in turn, regulates metabolic programming such as lipolysis and gluconeogenesis in adipose tissue and liver, respectively.<sup>25</sup>

IFN- $\gamma$  is a major T-cell cytokine. It has been postulated that a shift of T helper 1 over T helper 2 cytokines is observed in obesity and can promote inflammation in fat tissue. Also, IFN- $\gamma$  induced sustained loss of insulin-stimulated glucose uptake in human adipocytes, coincident with downregulation of the insulin receptor.<sup>23,26</sup> However, this relation has been

scarcely studied. Notwithstanding, this cytokine has been related to obesity as well as to IR in children.<sup>24</sup>

Despite the obesity pandemic, which has led to a parallel rise in the prevalence of pediatric forms of chronic diseases such as T2D, there is not an abundance of studies that show the participation of cytokines linking obesity and IR in children. The purpose of the study was to explore which of the aforementioned cytokines are able to identify IR and the metabolic alterations in eutrophic and obese Mexican children.

## Subjects and methods

This epidemiological study was conducted in nine middle socioeconomic class schools of Mexico City. Prior to the study, ethical clearance was obtained by both the ethics and research institutional boards of our hospital and school authorities; likewise, written informed consent was obtained from the participants and their parents in each of the two stages of the study.

The first stage was aimed to identify obese school-age children. For this purpose and following anthropometric international guidelines, a trained team of nurses measured the children's weight and height without shoes and wearing light clothing. Weight was taken using a digital scale (Seca, Hamburg, Germany) to the nearest 0.1 kg. Height was measured using a Seca 225 stadiometer to the nearest 0.1 cm. This screening was performed in 1,441 children between 6 and 12 years of age and eutrophic or obese status was assessed using the body mass index (BMI) percentiles according to the Centers for Disease Control and Prevention 2000 references (Atlanta, GA). Eutrophic status was considered when BMI was between the 25th and 75th percentile and obesity was considered when BMI was  $\geq$ 95th percentile for the child's age and gender. To establish a contrasting nutritional status, those children with BMI between 76 and  $\leq$ 95 pc were purposely excluded.

After classifying the participants, 200 obese and 200 eutrophic children were identified. From these, 186 eutrophic and 183 obese children accepted to participate in the following stage and complete blood samples were collected.

During the second stage, blood pressure was measured by the auscultatory method using a sphygmomanometer (ALPK2, Tokyo, Japan) with appropriate cuff size for arm width, following 2004 North American guidelines.<sup>27</sup> Four blood pressure readings were taken for each participant on the right arm in a sitting position, resting 1 min between each measurement and considering the blood pressure level as the mean of the last three readings. Waist circumference (WC) was measured at the midpoint between the lowest rib and the iliac crest after a normal exhalation with children in the standing position. In addition, after 12 h of fasting, blood was drawn to determine insulin by chemiluminescence immunoassay (IMMULITE 2000, Euro, DPC, Llanberis, UK), glucose, total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (ILAB 350, Instrumentation Laboratory, Barcelona, Spain).

Cytokines—IL-6, IFN- $\gamma$ , and resistin—were determined by ELISA method using R&D kits (Minneapolis, MN), and total adiponectin was determined with a Millipore kit (St. Charles, MO). Insulin resistance was assessed through HOMA-IR using the following equation:<sup>28</sup>

$$[\text{fasting glucose (mg/dL)} \times \text{fasting insulin (\mu U/mL)} / 405]$$

A 3.4 HOMA-IR value was the cut-off point to accept insulin resistance, corresponding to the 90th percentile of a population of healthy children. Values above this cut-off point were considered as cardiovascular risk factors.<sup>29</sup>

### Statistical analysis

Mean and standard deviation were obtained from the demographic, anthropometric and metabolic variables. Using BMI, subjects were categorized as eutrophic or obese and, in turn, obese subjects were classified according to

those who have or do not have IR. All measurements in each of the groups were compared using Student t test. Bivariate Spearman correlation analysis was performed for IR and metabolic and inflammatory factors. Using robust linear regression analysis with inflammatory markers as independent variables, the effect over HOMA-IR was assessed. For all analyses,  $p < 0.05$  values were considered statistically significant. Data were processed with STATA, SE v.11.0, and EPIINFO 3.3.2 according to the CDC 2000 reference.<sup>30</sup>

## Results

Anthropometric features, blood pressure, metabolic profile and cytokine concentrations of eutrophic and obese children with or without IR are shown in Table 1. Mean age of the participants was 9.5 years. The prevalence of IR in obese populations was 27.3%. Anthropometric and blood

**Table 1** Anthropometric, clinic, metabolic and inflammatory characteristics in eutrophic and obese with and without insulin resistance (IR) school children.

	Eutrophic	Obese	Obese		
	<i>n</i> = 186	<i>n</i> = 183	<i>p</i> value*	Without IR <i>n</i> = 133	With IR <i>n</i> = 50
				Mean $\pm$ SD	Mean $\pm$ SD
Age (years)	9.4 $\pm$ 1.8	9.6 $\pm$ 1.8	0.368	9.3 $\pm$ 1.8	10.4 $\pm$ 1.7
<b>Anthropometry</b>					<b>0.001</b>
Weight (kg)	29.8 $\pm$ 7.1	48.9 $\pm$ 12.8	<b>&lt;0.001</b>	45.9 $\pm$ 11.0	57.1 $\pm$ 13.7
Height (cm)	133.8 $\pm$ 12.1	140.0 $\pm$ 11.7	<b>&lt;0.001</b>	137.5 $\pm$ 10.7	146.6 $\pm$ 11.7
WC (cm)	57.7 $\pm$ 4.8	79.0 $\pm$ 9.1	<b>&lt;0.001</b>	76.9 $\pm$ 8.2	84.7 $\pm$ 8.9
BMI (kg/m <sup>2</sup> )	16.4 $\pm$ 1.3	24.5 $\pm$ 2.7	<b>&lt;0.001</b>	23.9 $\pm$ 2.5	26.2 $\pm$ 2.8
BMI percentile <sup>a</sup>	45.9 $\pm$ 18.1	97.4 $\pm$ 1.3	<b>&lt;0.001</b>	97.2 $\pm$ 1.3	97.7 $\pm$ 1.1
<b>Blood pressure (mm/Hg)</b>					<b>0.030</b>
SBP	88.7 $\pm$ 7.8	97.8 $\pm$ 8.8	<b>&lt;0.001</b>	96.8 $\pm$ 8.4	100.4 $\pm$ 9.4
SBP percentile <sup>b</sup>	17.4 $\pm$ 18.1	33.8 $\pm$ 22.9	<b>&lt;0.001</b>	33.6 $\pm$ 21.9	34.2 $\pm$ 25.4
DBP	56.0 $\pm$ 7.1	62.2 $\pm$ 7.6	<b>&lt;0.001</b>	61.3 $\pm$ 7.4	64.3 $\pm$ 7.8
DBP percentile <sup>b</sup>	38.2 $\pm$ 21.0	53.6 $\pm$ 21.5	<b>&lt;0.001</b>	52.5 $\pm$ 21.2	56.4 $\pm$ 22.1
<b>Metabolic</b>					<b>0.015</b>
Glucose (mg/dL)	89.3 $\pm$ 11.0	89.1 $\pm$ 10.4	0.818	87.7 $\pm$ 10.1	92.8 $\pm$ 10.3
Insulin (mU/mL)	5.0 $\pm$ 3.0	12.5 $\pm$ 9.7	<b>&lt;0.001</b>	8.1 $\pm$ 3.3	24.1 $\pm$ 11.3
HOMA-IR <sup>c</sup>	1.1 $\pm$ 0.7	2.8 $\pm$ 2.1	<b>&lt;0.001</b>	1.8 $\pm$ 0.7	5.4 $\pm$ 2.3
Triglycerides (mg/dL)	80.8 $\pm$ 32.2	123.0 $\pm$ 64.9	<b>&lt;0.001</b>	111.8 $\pm$ 50.4	152.5 $\pm$ 86.9
Total cholesterol (mg/dL)	151.4 $\pm$ 35.8	151.2 $\pm$ 39.0	0.966	152.0 $\pm$ 39.5	149.0 $\pm$ 37.9
HDL-C (mg/dL)	52.9 $\pm$ 13.5	43.2 $\pm$ 11.8	<b>&lt;0.001</b>	44.2 $\pm$ 11.4	40.6 $\pm$ 12.6
LDL-C (mg/dL)	96.2 $\pm$ 27.5	98.5 $\pm$ 28.1	0.419	98.8 $\pm$ 27.9	97.7 $\pm$ 28.9
<b>Inflammatory markers</b>					<b>0.064</b>
IL-6 (pg/mL)	36.3 $\pm$ 72.7	25.6 $\pm$ 43.3	0.085	23.8 $\pm$ 42.0	30.4 $\pm$ 46.7
IFN- $\gamma$ (pg/mL)	493.0 $\pm$ 680.7	440.4 $\pm$ 676.7	0.463	390.4 $\pm$ 623.4	567.4 $\pm$ 789.0
Adiponectin (μg/mL)	15.5 $\pm$ 6.1	12.0 $\pm$ 4.8	<b>&lt;0.001</b>	12.5 $\pm$ 5.0	10.8 $\pm$ 4.2
Resistin (ng/mL)	12.0 $\pm$ 7.5	12.4 $\pm$ 7.7	0.670	11.7 $\pm$ 7.5	14.2 $\pm$ 7.8

SBP, systolic blood pressure; DBP, diastolic blood pressure; WC, waist circumference; BMI, body mass index.

*p* values  $< 0.05$  are indicated in boldface.

<sup>a</sup>According to CDC 2000.

<sup>b</sup>According to The National High Blood Pressure Education Program.

<sup>c</sup>HOMA-IR: [(fasting glucose (mg/dL))(fasting insulin (μU/mL)) / 405].

\*Student t test.

\*\*Student t test was performed after log-transformation of values.

pressure values were different between eutrophic and obese participants and also between obese children with or without IR ( $p < 0.05$ ). In terms of metabolic variables, obese children with IR exhibited higher values of glucose, insulin, HOMA-IR and triglycerides than obese children without IR and eutrophic children. Another parameter showing differences was HDL-C in which the obese group showed the lowest values ( $p < 0.001$ ).

Adiponectin values were inversely correlated with nutritional status. Eutrophic children had higher values than obese children ( $p < 0.001$ ). Interestingly, the obese group with IR showed lower concentrations of adiponectin and higher concentrations of resistin than the obese group of children without IR ( $p < 0.05$ ).

Table 2 shows the correlations between the levels of inflammatory markers with metabolic and anthropometric features in both eutrophic and obese children. It describes that adiponectin values in eutrophic children were inversely related with insulin and HOMA-IR, whereas IL-6 and IFN- $\gamma$  showed a direct association ( $p < 0.05$ ). The correlation between impairment of IR components and adiponectin, although observed in both eutrophic and obese children, was

stronger in obese children. Likewise, systolic blood pressure and triglycerides showed a significant inverse association in these groups. On the contrary, a direct correlation was observed between resistin and insulin ( $\rho = 0.16$ ,  $p = 0.033$ ). Adiponectin in both eutrophic and obese children showed inverse correlations with WC values ( $p = 0.001$ ).

Table 3 shows, in whole populations, how HOMA-IR coefficients decrease, whereas adiponectin units increase. These changes remained significant after adjusting by gender, age, and BMI categories. HOMA-IR decreased 0.04 units (95% CI 0.004; 0.041) for unit change of adiponectin. Whereas the association with resistin was opposite, HOMA-IR units increased 0.02 by unit of change in resistin ( $p = 0.018$ ).

## Discussion

The results of this study, which explored the effects of inflammatory cytokines on IR in children with contrasting nutritional status, showed that HOMA-IR values were inversely related with adiponectin concentrations and directly associated with resistin. However, the adiponectin

**Table 2** Correlation between inflammatory markers, waist circumference, blood pressure, insulin resistance and metabolic profile, according to nutritional status.

	IL-6		IFN- $\gamma$		Adiponectin		Resistin	
	<i>rho</i>	<i>p</i>	<i>rho</i>	<i>p</i>	<i>rho</i>	<i>p</i>	<i>rho</i>	<i>p</i>
<b>Eutrophic</b>								
<i>Anthropometry</i>								
WC (cm)	0.03	0.704	0.00	0.973	-0.23	<b>0.001</b>	-0.05	0.525
<i>Blood pressure (mmHg)</i>								
SBP	0.00	<b>0.989</b>	0.02	0.742	-0.09	0.215	0.04	0.538
DBP	0.01	<b>0.894</b>	-0.02	0.810	-0.10	0.179	0.08	0.250
<i>Metabolic (mg/dL)</i>								
Glucose	-0.01	<b>0.839</b>	0.00	0.951	0.06	0.426	-0.06	0.407
Insulin (mU/mL)	0.16	<b>0.030</b>	0.20	<b>0.005</b>	-0.18	<b>0.013</b>	0.14	0.060
HOMA-IR	0.17	<b>0.021</b>	0.22	<b>0.002</b>	-0.18	<b>0.013</b>	0.11	0.120
Triglycerides	-0.05	0.501	-0.02	0.728	-0.04	0.580	0.06	0.391
Total cholesterol	-0.08	0.269	-0.14	<b>0.044</b>	0.01	0.843	-0.18	<b>0.010</b>
HDL-C	-0.05	0.508	-0.09	0.212	0.06	0.373	-0.13	0.063
<b>Obese</b>								
<i>Anthropometry</i>								
WC (cm)	-0.03	<b>0.697</b>	0.06	0.414	-0.28	<b>&lt;0.001</b>	-0.08	0.308
<i>Blood pressure (mmHg)</i>								
SBP	0.02	<b>0.777</b>	0.09	0.205	-0.17	<b>0.021</b>	-0.08	0.275
DBP	0.09	<b>0.201</b>	0.05	0.497	-0.03	0.674	-0.07	0.365
<i>Metabolic (mg/dL)</i>								
Glucose	0.14	<b>0.053</b>	-0.01	0.846	-0.17	<b>0.017</b>	-0.06	0.449
Insulin (mU/mL)	0.00	<b>0.958</b>	0.10	0.158	-0.23	<b>0.002</b>	0.16	<b>0.033</b>
HOMA-IR	0.02	<b>0.776</b>	0.12	0.099	-0.25	<b>0.001</b>	0.14	0.060
Triglycerides	-0.17	<b>0.017</b>	-0.10	0.170	-0.22	<b>0.003</b>	-0.14	0.064
Total cholesterol	0.01	<b>0.869</b>	-0.12	0.109	-0.04	0.603	-0.29	<b>&lt;0.001</b>
HDL-C	0.09	<b>0.218</b>	-0.09	0.203	0.13	0.075	-0.14	<b>0.050</b>

WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IR, homeostasis model of assessment of insulin resistance index.

Values are Spearman correlation coefficients (*rho*).

*p* values  $< 0.05$  are indicated in boldface.

**Table 3** Association of inflammatory markers with HOMA-IR in linear regression models.

	Model 1			Model 2		
	Coeff	95% CI	p	Coeff	95% CI	p
IL-6	-0.001	-0.003; 0.002	0.680	-0.001	-0.002; 0.002	0.966
IFN- $\gamma$	0.001	-0.001; 0.001	0.405	0.001	-0.001; 0.001	0.620
Adiponectin	-0.039	-0.065; -0.013	<b>0.004</b>	-0.040	-0.066; -0.014	<b>0.003</b>
Resistin	0.024	0.004; 0.043	<b>0.017</b>	0.022	0.004; 0.041	<b>0.018</b>

Model 1 is adjusted for BMI categories (1 = BMI percentile <85; 2 = BMI percentile >95).

Model 2 is adjusted for BMI categories, age and gender.

p values <0.05 are indicated in boldface.

effect was observed in both obese and eutrophic children, whereas resistin was observed only in obese children.

Although there are reports in which adiponectin is not useful for prediction of IR and metabolic syndrome features,<sup>19,20</sup> results of the present study agree with most literature reports<sup>17,18</sup> that show that adiponectin is consistently negatively correlated with body weight and HOMA-IR values in obese children. Although to a lesser degree than obese children, the same effect was seen in eutrophic children.

Additionally, studies in obese children addressed for weight reduction have shown that adiponectin concentrations increase, whereas IR improves in those patients who lose weight.<sup>22,31-34</sup> Likewise, due to the fact that low plasma concentrations could precede changes of IR not only in obese subjects but also in eutrophic children, this supports the idea that adiponectin could be used as a biomarker to assess metabolic changes and to predict IR in both obese and eutrophic children<sup>8</sup> as well as in metabolic syndrome<sup>8</sup> and T2D.<sup>35</sup>

In addition, high adiponectin values had an inverse association with triglycerides, whereas they had a direct association with HDL-C (data not shown) as reported by other authors.<sup>36</sup>

Regarding resistin, which has been proposed as a hormone linking obesity with T2D in humans, it currently remains controversial because support for the above-proposed information comes from experimental rodent studies<sup>37</sup> that show a strong correlation with IR and obesity that upregulates their production, whereas amelioration of obesity produces a downregulation.<sup>38</sup>

Currently, the role of resistin on IR in children is not well understood due to contradictory study results.<sup>39</sup> Some find positive associations,<sup>40,41</sup> whereas others do not.<sup>21,42-44</sup>

Our results show that resistin concentrations are higher in obese than in eutrophic children and also are higher in obese children with IR than in obese children without IR. Likewise, in these children this cytokine has a strong association with HOMA-IR even after adjustment for gender and nutritional status, confirming that resistin is positively associated with IR.

According to this theory, it has been shown in longitudinal interventions for weight reduction that in those patients who remain at the same weight, resistin increases,<sup>22</sup> which could be interpreted as the persistence of low-grade inflammation. Additionally, when obese patients with glucose intolerance receive metformin to ameliorate their problem, it is

observed that resistin concentration reduces, probably because metformin affects the resistin gene expression as well as activating the AMPK/LKB1 pathway, eliminating some of the abnormal resistin regulation.<sup>45</sup>

IL-6 and IFN- $\gamma$  have been related with IR in both adults and children.<sup>11,46,47</sup> Other studies have shown that after weight reduction in children, IL-6 decreases, with improvement of insulin sensitivity.<sup>48,49</sup>

Likewise, results from the present study show that both IL-6 and IFN- $\gamma$  are correlated with HOMA-IR values. However, when each was correlated, there was a lack of effect even after adjusting the model by age and gender. This has also been reported elsewhere.<sup>50</sup>

The present study is observational and cross-sectional, with the limitation that by using between study variables it is not possible to establish causality. However, given the close relationship between obesity, chronic low-grade inflammation and IR with the attendant risk of developing comorbidities such as T2D even in children, it is imperative to deal with the problem by looking for early biomarkers with the aim of recognizing the problem.

Preventing IR means preventing obesity from the early stages of life through modification of lifestyles and obesogenic environments. The low grade of inflammation produced by obesity is a common way for developing, in the short term, IR and diseases such as T2D which, in turn, are the leading causes of mortality in adults. It is necessary to prioritize and to understand and prevent these alterations from early ages.

This study has confirmed that among obese children, regardless of age and gender, increasing figures of resistin or decrease of adiponectin are associated with the presence of IR and metabolic disorders. Therefore, these could be used as reliable biomarkers for predicting IR in obese children.

Additionally, when adiponectin values increase in eutrophic children, it is possible to observe a decrease in insulin concentrations and HOMA-IR values. This observation may support the idea that adiponectin is an early biomarker of IR, not only in obese subjects but also in eutrophic subjects.

In conclusion, among cytokines, adiponectin, which is an anti-inflammatory, was negatively associated with IR in both obese and eutrophic children, although to a lesser magnitude in eutrophic subjects. On the other hand, the pro-inflammatory IL-6 and IFN- $\gamma$  were directly associated with obesity and IR. Resistin was directly associated with

obese children, particularly those who had IR, supporting the idea that this cytokine is involved in the inflammatory process produced by obesity. Finally, the plasma behavior of this adipocytokine could be used to monitor the previously mentioned metabolic alterations.

## Conflict of interest

The authors declare no conflict of interest of any nature.

## References

1. Lobstein T, Baur L, Uauy R; IASO International Obesity Task Force. Obesity in children and young people: a crisis in public health. *Obes Rev*. 2004;5(suppl 1):4-104.
2. Bonvecchio A, Safran M, Monterrubio EA, Gust T, Villalpando S, Rivera JA. Overweight and obesity trends in Mexican children 2 to 18 years of age from 1988 to 2006. *Salud Publica Mex*. 2009;51(suppl 4):S586-S594.
3. Olaiz-Fernández G, Rivera-Dommarco J, Shamah-Levy T, Rojas R, Villalpando-Hernández S, Hernández-Avila M, et al. Encuesta Nacional de Salud y Nutrición 2006. Cuernavaca, México: Instituto Nacional de Salud Pública; 2006.
4. Gutierrez JP, Rivera-Dommarco J, Shamah-Levy T, Villalpando-Hernandez S, Franco A, Cuevas-Nasu L, et al. Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales. Cuernavaca, México: Instituto Nacional de Salud Pública (MX); 2012.
5. Speakman JR. Obesity: the integrated roles of environment and genetics. *J Nutr*. 2004;134(suppl 8):2090S-2105S.
6. Cruz M, Torres M, Aguilar-Herrera B, Pérez-Johnston R, Guzmán-Juárez N, Aranda M, et al. Type 2 diabetes mellitus in children—an increasing health problem in Mexico. *J Pediatr Endocrinol Metab*. 2004;17:183-190.
7. Flores-Huerta S, Klunder-Klunder M, Reyes-de-la-Cruz L, Santos JI. Increase in body mass index and waist circumference is associated with high blood pressure in children and adolescents in Mexico City. *Arch Med Res*. 2009;40:208-15.
8. Klunder-Klunder M, Flores-Huerta S, Garcia-Macedo R, Peralta-Romero J, Cruz M. Adiponectin in eutrophic and obese children as a biomarker to predict metabolic syndrome and each of its components. *BMC Public Health*. 2013;13:88.
9. Valle M, Martos R, Gascón F, Cañete R, Zafra MA, Morales R. Low-grade systemic inflammation, hypoadiponectinemia and a high concentration of leptin are present in very young obese children, and correlate with metabolic syndrome. *Diabetes Metab*. 2005;31:55-62.
10. Arslan N, Erdur B, Aydin A. Hormones and cytokines in childhood obesity. *Indian Pediatr*. 2010;47:829-39.
11. Herder C, Schneitler S, Rathmann W, Haastert B, Schneitler H, Winkler H, et al. Low-grade inflammation, obesity, and insulin resistance in adolescents. *J Clin Endocrinol Metab*. 2007;92:4569-74.
12. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. *Diabetes Metab*. 2008;34:2-11.
13. You T, Yang R, Lyles MF, Gong D, Nicklas BJ. Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors. *Am J Physiol Endocrinol Metab*. 2005;288:E741-E747.
14. Chiarelli F, Marcovecchio ML. Insulin resistance and obesity in childhood. *Eur J Endocrinol*. 2008;159(suppl 1):S67-S74.
15. Musaad S, Haynes EN. Biomarkers of obesity and subsequent cardiovascular events. *Epidemiol Rev*. 2007;29:98-114.
16. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? *Diabetes Care*. 2003;26:2442-2450.
17. Medina-Bravo P, Meza-Santibáñez R, Rosas-Fernández P, Galván-Duarte R, Saucedo-García R, Velázquez-López L, et al. Decrease in serum adiponectin levels associated with visceral fat accumulation independent of pubertal stage in children and adolescents. *Arch Med Res*. 2011;42:115-21.
18. Rasmussen-Torvik LJ, Pankow JS, Jacobs DR Jr, Steinberger J, Moran AM, Sinaiko AR. Influence of waist on adiponectin and insulin sensitivity in adolescence. *Obesity (Silver Spring)*. 2009;17:156-61.
19. Cizmecioğlu FM, Etiler N, Ergen A, Gormus U, Keser A, Hekim N, et al. Association of adiponectin, resistin and high sensitive CRP level with the metabolic syndrome in childhood and adolescence. *Exp Clin Endocrinol Diabetes*. 2009;117:622-7.
20. Snehalatha C, Yamuna A, Ramachandran A. Plasma adiponectin does not correlate with insulin resistance and cardiometabolic variables in nondiabetic Asian Indian teenagers. *Diabetes Care*. 2008;31:2374-9.
21. Reinehr T, Roth CL, Menke T, Andler W. Resistin concentrations before and after weight loss in obese children. *Int J Obes (Lond)*. 2006;30:297-301.
22. Roth CL, Kratz M, Ralston MM, Reinehr T. Changes in adipose-derived inflammatory cytokines and chemokines after successful lifestyle intervention in obese children. *Metabolism*. 2011;60:445-52.
23. Rocha VZ, Folco EJ, Sukhova G, Shimizu K, Gotsman I, Vernon AH, et al. Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. *Circ Res*. 2008;103:467-76.
24. Pacifico L, Di Renzo L, Anania C, Osborn JF, Ippoliti F, Schiavo E, et al. Increased T-helper interferon-gamma-secreting cells in obese children. *Eur J Endocrinol*. 2006;154:691-7.
25. Spiegelman BM. Transcriptional control of energy homeostasis through the PGC1 coactivators. In: Novartis Foundation Symposium 286. Fatty Acids and Lipotoxicity in Obesity and Diabetes. Beijing: John Wiley & Sons; 2007. p. 3-12.
26. McGillicuddy FC, Chiquoine EH, Hinkle CC, Kim RJ, Shah R, Roche HM, et al. Interferon gamma attenuates insulin signaling, lipid storage, and differentiation in human adipocytes via activation of the JAK/STAT pathway. *J Biol Chem*. 2009;284:31936-44.
27. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics*. 2004;114 (2 suppl 4<sup>th</sup> report):555-76.
28. Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. *Pediatrics*. 2005;115:e500-503.
29. García-Cuartero B, García-Lacalle C, Jiménez-Lobo C, González-Vergaz A, Calvo-Rey C, Alcázar-Villar MJ, et al. Índice HOMA y QUICKI, insulina y péptido C en niños sanos. Puntos de corte de riesgo cardiovascular. *An Pediatr (Barc)*. 2007;66: 481-90.
30. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, et al. 2000 CDC Growth Charts for the United States: methods and development. *Vital Health Stat* 11. 2002; (246):1-190.
31. Cambuli VM, Musiu MC, Incaní M, Paderi M, Serpe R, Marras V, et al. Assessment of adiponectin and leptin as biomarkers of positive metabolic outcomes after lifestyle intervention in overweight and obese children. *J Clin Endocrinol Metab*. 2008;93:3051-7.

32. Reinehr T, Roth C, Menke T, Andler W. Adiponectin before and after weight loss in obese children. *J Clin Endocrinol Metab*. 2004;89:3790-4.

33. Kopp HP, Krzyzanowska K, Möhlig M, Spranger J, Pfeiffer AFH, Schernthaner G. Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. *Int J Obes (Lond)*. 2005;29:766-71.

34. Martos-Moreno GA, Barrios V, Martínez G, Hawkins F, Argente J. Effect of weight loss on high-molecular weight adiponectin in obese children. *Obesity (Silver Spring)*. 2010;18:2288-94.

35. Cruz M, García-Macedo R, García-Valerio Y, Gutiérrez M, Medina-Navarro R, Durán G, et al. Low adiponectin levels predict type 2 diabetes in Mexican children. *Diabetes Care*. 2004;27:1451-3.

36. Bacha F, Saad R, Gungor N, Arslanian SA. Adiponectin in youth. Relationship to visceral adiposity, insulin sensitivity, and  $\beta$ -cell function. *Diabetes Care*. 2004;27:547-52.

37. Kusminski CM, McTernan PG, Kumar S. Role of resistin in obesity, insulin resistance and type II diabetes. *Clin Sci (Lond)*. 2005;109:243-56.

38. Schwartz DR, Lazar MA. Human resistin: found in translation from mouse to man. *Trends Endocrinol Metab*. 2011;22:259-65.

39. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin—the classical, resistin—the controversial, adiponectin—the promising, and more to come. *Best Pract Res Clin Endocrinol Metab*. 2005;19:525-46.

40. Abdelghaffar S, Hafez MH, Shaaban FA, Abou Esmail LA, Salama SI, Rashed RG. Resistin and obesity-associated insulin resistance in children. *J Am Sci*. 2010;6:256-66.

41. Rubin DA, McMurray RG, Harrell JS, Hackney AC, Thorpe DE, Haqq AM. The association between insulin resistance and cytokines in adolescents: the role of weight status and exercise. *Metabolism*. 2008;57:683-90.

42. Al-Daghri NM, Al-Attas OS, Alokail MS, Alkharfy KM, Draz HM. Relationship between resistin and aPAI-1 levels with insulin resistance in Saudi children. *Pediatr Int*. 2010;52:551-6.

43. Li M, Fisette A, Zhao XY, Deng JY, Mi J, Cianflone K. Serum resistin correlates with central obesity but weakly with insulin resistance in Chinese children and adolescents. *Int J Obes (Lond)*. 2009;33:424-39.

44. Zou CC, Liang L, Hong F. Relationship between insulin resistance and serum levels of adiponectin and resistin with childhood obesity. *Indian Pediatr*. 2007;44:275-9.

45. Gómez-Díaz RA, Talavera JO, Pool EC, Ortiz-Navarrete FV, Solórzano-Santos F, Mondragón-González R, et al. Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial. *Metabolism*. 2012;61:1247-55.

46. Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. *J Clin Endocrinol Metab*. 2002;87:2084-9.

47. Yeste D, Vendrell J, Tomasin R, Broch M, Gussinyé M, Megia A, et al. Interleukin-6 in obese children and adolescents with and without glucose intolerance. *Diabetes Care*. 2007;30:1892-4.

48. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. *J Clin Endocrinol Metab*. 2000;85:3338-42.

49. Garanty-Bogacka B, Syrenicz M, Goral J, Krupa B, Syrenicz J, Walczak M, et al. Changes in inflammatory biomarkers after successful lifestyle intervention in obese children. *Endokrynol Pol*. 2011;62:499-505.

50. Galcheva SV, Iotova VM, Yotov YT, Bernasconi S, Street ME. Circulating proinflammatory peptides related to abdominal adiposity and cardiometabolic risk factors in healthy prepubertal children. *Eur J Endocrinol*. 2011;164:553-8.